OPHT - Ophthotech Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Ophthotech Corporation

One Penn Plaza
19th Floor
New York, NY 10119
United States

Full Time Employees44

Key Executives

Dr. David R. Guyer M.D.Co-Founder & Exec. Chairman960.71k7.87M57
Mr. Glenn P. Sblendorio M.B.A.Pres, CEO & Director746.11kN/A61
Dr. Samir C. Patel M.D.Co-Founder and Consultant947.79k468.62k56
Ms. Barbara A. Wood Esq.Sr. VP, Gen. Counsel & Sec.551.43k51.88k54
Mr. David F. Carroll M.B.A.CFO & TreasurerN/AN/A51
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.

Corporate Governance

Ophthotech Corporation’s ISS Governance QualityScore as of December 1, 2017 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.